Research

Celltrion Announces Positive Pre-clinical Results for COVID- 19 Antiviral Antibody Treatment, Showing Improvement in Recovery Time

Monday, June 1, 2020 - 2:00am

Celltrion Group today announced positive pre-clinical results for its COVID-19 antiviral antibody treatment, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2, the virus causing COVID-19.

Key Points: 
  • Celltrion Group today announced positive pre-clinical results for its COVID-19 antiviral antibody treatment, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2, the virus causing COVID-19.
  • The trial set out to assess the efficacy of two dosage amounts (low and high) for the antiviral antibody treatment.
  • This announcement follows the identification of antibody candidates for an antiviral treatment which Celltrion completed in April.
  • In response to these positive results, Celltrion will now conduct additional efficacy and toxicity testing in pre-clinical settings and anticipates starting first-in-human clinical trials in July.

City of Hope Physicians Present Innovative Cancer Research at ASCO20 Virtual Session

Saturday, May 30, 2020 - 11:00am

The ASCO annual meeting brings together City of Hope and other leading cancer clinicians who are dedicated to sharing knowledge that will ultimately benefit patients."

Key Points: 
  • The ASCO annual meeting brings together City of Hope and other leading cancer clinicians who are dedicated to sharing knowledge that will ultimately benefit patients."
  • City of Hope doctors and scientists will present oral and poster presentations on a wide array of topics.
  • City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases.
  • A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is the highest ranked cancer hospital in the West, according to U.S. News & World Reports Best Hospitals: Specialty Ranking.

Newron Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Friday, May 29, 2020 - 9:01pm

Newron Pharmaceuticals S.p.A. (Newron) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will present at the upcoming Jefferies Virtual Healthcare Conference on Tuesday, June 2nd, 2020 at 9:30 a.m. EDT.

Key Points: 
  • Newron Pharmaceuticals S.p.A. (Newron) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will present at the upcoming Jefferies Virtual Healthcare Conference on Tuesday, June 2nd, 2020 at 9:30 a.m. EDT.
  • Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system.
  • Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories.
  • Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.

Onduo Appoints Verily’s Dr. Vindell Washington as Interim CEO to Lead Next Phase of Growth

Friday, May 29, 2020 - 9:30pm

Today, Onduo announced Dr. Vindell Washington will step in as interim CEO to lead the company during its next stage of growth.

Key Points: 
  • Today, Onduo announced Dr. Vindell Washington will step in as interim CEO to lead the company during its next stage of growth.
  • Dr. Josh Riff, who has served as CEO since the launch of Onduo in 2016 is leaving to pursue other early-stage entrepreneurial opportunities.
  • Washington previously served as chief medical officer and EVP at Blue Cross Blue Shield of Louisiana, where he oversaw the population disease management operation.
  • It's been exciting to learn about Verilys broad commitment to developing not only the solutions, but also businesses to drive change in the healthcare system, added Washington.

Biocom Supports California Life Science Companies with Best Practices Guide for Safely Returning to the Workplace

Friday, May 29, 2020 - 7:55pm

Biocom, the association representing the California life science industry, today announced that it has published a guide tailored to life science companies with recommendations on how to safely return to the workplace as stay-at-home restrictions enacted in response to the COVID-19 pandemic are eased.

Key Points: 
  • Biocom, the association representing the California life science industry, today announced that it has published a guide tailored to life science companies with recommendations on how to safely return to the workplace as stay-at-home restrictions enacted in response to the COVID-19 pandemic are eased.
  • The Path Forward, Biocoms Return to Work Guide for Californias Life Science Industry is designed to assist small- and medium-sized life science companies by providing industry best practices for preparing their facilities to meet new workplace safety guidelines.
  • These are aimed toward preventing the spread of the novel coronavirus and safely bringing employees back into the office, laboratory and manufacturing facilities.
  • Biocom assembled a task force of California life science industry professionals with expertise in environmental health and safety, human resources, operations and communications to lead this effort of aiding smaller companies through the re-opening process.

Rockland Develops Antibody Proven to Detect SARS-CoV-2 in Patient Samples

Friday, May 29, 2020 - 7:20pm

Rockland Immunochemicals Inc. has developed a critical antibody reagent essential to antibody tests used to determine SARS-CoV-2 exposure for patients suspected to have contracted COVID-19 .

Key Points: 
  • Rockland Immunochemicals Inc. has developed a critical antibody reagent essential to antibody tests used to determine SARS-CoV-2 exposure for patients suspected to have contracted COVID-19 .
  • This antibody has proven effective in lateral flow assays (immunochromatography), ELISA, Western blotting, Immunofluorescence microscopy, fluorescence-activated cell sorting, and immunohistochemistry.
  • Dr. Carl Ascoli, Chief Science Officer for Rockland Immunochemicals Inc. stated that, This antibody is invaluable for the highly accurate detection of SARS-CoV-2 and subsequently COVID-19 disease in various types of patient samples, including nasal and throat swab extracts and saliva.
  • Rockland is currently in large scale production of this antibody for deployment in rapid tests that can be manufactured and distributed widely.

Quanterix Expands Menu of Ultra-Sensitive Neurology Assays with Simoa® P-Tau181 V2 Kit for Improved Detection and Study of Alzheimer’s Disease

Friday, May 29, 2020 - 5:37pm

Importantly, there is no objective test to diagnose the disorder, leading many physicians to rely solely on subjective cognitive assessments.

Key Points: 
  • Importantly, there is no objective test to diagnose the disorder, leading many physicians to rely solely on subjective cognitive assessments.
  • For years, researchers have studied the utility of biomarkers for understanding, detecting and monitoring Alzheimers disease.
  • P-tau181 shows immense promise in this regard, which is augmented considerably when harnessed by a leader in detection like Quanterix.
  • The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease.

Creatv Announces Positive Results for the LifeTracDx Blood Test in the Detection of Early Stage Cancer in Multiple Solid Tumors

Friday, May 29, 2020 - 5:35pm

Creatv MicroTech , a privately-held biotechnology company has pioneered a blood test for the universal screening of early stage cancer.

Key Points: 
  • Creatv MicroTech , a privately-held biotechnology company has pioneered a blood test for the universal screening of early stage cancer.
  • This represents a significant step towards pan cancer screening by a routine blood draw with high sensitivity and specificity.
  • Creatvs poster, Circulating Stromal Cells as a Blood Based Biomarker for Screening Invasive Solid Tumors, Abstract ID: 3535, highlights the performance of the LifeTracDxTM blood test.
  • Creatv is a privately-held cancer screening and diagnostic company founded in 2000, featuring expertise in both biodetection and microfabrication.

Nanobiotix Announces Positive First Results From Phase I Expansion in Locally Advanced Head and Neck Cancer at ASCO 2020

Friday, May 29, 2020 - 5:02pm

The data were published as part of the virtual scientific program at the 2020 annual meeting of the American Society for Clinical Oncology (ASCO).

Key Points: 
  • The data were published as part of the virtual scientific program at the 2020 annual meeting of the American Society for Clinical Oncology (ASCO).
  • To date, 40 patients have been recruited, 30 of whom are evaluable for efficacy and are included in the data presented at ASCO 2020.
  • Regarding the new, expansion part data, analysis of 40 patients dosed showed that NBTXR3 activated by radiation therapy remains safe and well tolerated.
  • In the United States, the Company has started the regulatory process to commence a phase III clinical trial in locally advanced head and neck cancers.

Personalis, Inc. Announces New Data to be Presented at ASCO Virtual Scientific Meeting

Friday, May 29, 2020 - 4:08pm

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patients cancer and immune response.

Key Points: 
  • Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patients cancer and immune response.
  • Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes.
  • The Personalis Clinical Laboratory is GxP-aligned as well as CLIA88-certified and CAP-accredited.
  • For example, forward-looking statements include statements regarding the future availability, features or potential uses of the ImmunoID NeXT Platform or NeXT Dx Test and other future events.